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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.11.029Objective: The phosphoinositide-3 kinase signaling pathway is implicated in the
development of malignancy and promotes cell-cycle progression and resistance to
apoptosis. Malignant mesothelioma tumor specimens demonstrate high levels of the
phosphoinositide-3 kinase downstream mediator phosphorylated Akt. Exposure of
mesothelioma cell lines to LY294002, a phosphoinositide-3 kinase inhibitor, results
in apoptotic cell death and decreased phosphorylated Akt in vitro and tumor burden
reduction in vivo. Phosphoinositide-3 kinase is activated by cell-surface receptor
tyrosine kinases. We sought to determine which receptors are present in mesothe-
lioma and their role in cellular survival and phosphoinositide-3 kinase signaling.
Methods: Western blot analysis was performed to determine the relative expression
of epidermal growth factor receptor, insulin-like growth factor receptor, and platelet-
derived growth factor receptor in the mesothelioma cell lines I-45 and REN and the
mesothelial line Met5a. After exposure of mesothelioma lines to kinase inhibitors,
a cell viability assay was performed, cell-cycle analysis was performed to determine
the percentage of apoptosis, and Western blot analysis was performed for phos-
phorylated Akt.
Results: Inhibition of epidermal growth factor receptor resulted in apoptotic cell
death and Akt hypophosphorylation in mesothelioma cell lines. Insulin-like growth
factor receptor inhibition led to apoptotic cell death without affecting Akt phos-
phorylation. Platelet-derived growth factor receptor inhibition did not affect cellular
survival or phosphoinositide-3 kinase signaling.
Conclusion: In malignant mesothelioma constitutive activation of phosphoinositide-3
kinase/Akt results in cellular survival and contributes to the malignant phenotype.
We have demonstrated that epidermal growth factor receptor inhibition leads to
apoptotic cell death through downregulation of phosphoinositide-3 kinase signaling
in mesothelioma cell lines, whereas insulin-like growth factor receptor inhibition
leads to apoptosis independent of phosphoinositide-3 kinase. Epidermal growth
factor receptor, insulin-like growth factor receptor, and phosphoinositide-3 kinase
inhibition might be clinically relevant in malignant mesothelioma.
Malignant mesothelioma (MM) is an aggressive neoplasm arising fromthe serosal surfaces of the pleural and peritoneal cavities. The inci-dence of this disease has increased steadily since 1970, and there are
currently an estimated 3000 new cases per year in the United States. This trend
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asbestos exposure from the 1940s to the 1960s. Recent
studies have implicated exposure to SV40 tumor virus as
well.1,2 Mesotheliomas arise from multipotential me-
sothelial cells that are capable of differentiating into an
epithelial, sarcomatoid, or mixed neoplasm. The biologic
behavior of mesothelioma remains poorly understood,
and its clinical management is controversial. The treat-
ment of mesothelioma has been disappointing because
most patients die within 12 to 16 months of diagnosis,
regardless of treatment regimen. Radiation therapy alone
is generally ineffective because of the large volume of
the primary tumor and its proximity to vital mediastinal
structures, and response rates to chemotherapy have gen-
erally been less than 20%.3 Highly selected patients
appear to benefit from trimodality therapy consisting of
aggressive surgical resection followed by adjuvant radi-
ation and chemotherapy.4 Failure of conventional thera-
pies has led to interest in novel treatment approaches,
including prodrug gene therapy, downregulation of the
antiapoptotic gene product bcl-xl with histone deacety-
lase inhibition and antisense oligonucleotide strategies,
and immunotherapy.5-8
The phosphoinositide-3 kinase (PI3K)/Akt signaling
pathway is increasingly implicated in the development of
a number of solid tumors, as well as their resistance to
therapeutic measures, such as radiation and chemothera-
py.9-12 Akt is a serine/threonine kinase that is constitu-
tively activated in many human malignancies. The acti-
vation of Akt occurs downstream of PI3K. Activated
PI3K generates a lipid second messenger, which is es-
sential for translocation of Akt to the plasma membrane,
where it is phosphorylated and activated by phosphoi-
nositide-dependent kinase 1. Phosphorylated Akt then
conveys downstream signals, promoting cellular prolifera-
tion and survival over apoptosis.13,14 Activity of the PI3K/Akt
pathway is negatively regulated by the phosphatase and
tensin analog (PTEN) tumor suppressor gene. We have
previously demonstrated that forced overexpression of
PTEN in MM cell lines by adenoviral gene transfer resulted
in Akt hypophosphorylation and apoptotic cell death.15 We
have also demonstrated that resected mesothelioma speci-
mens exhibit high levels of phosphorylated Akt on immu-
nohistochemistry, indicating constitutive activation of this
signaling pathway. Furthermore, PI3K inhibition resulted in
Akt hypophosphorylation, engendered apoptotic cell death
in vitro, and resulted in reduction of tumor burden in vivo in
a mouse xenograft model of mesothelioma (manuscript
submitted).
PI3K is recruited to the cell membrane and activated by the
ligand-dependent activation of growth factor receptor tyrosine
kinases (RTKs). These growth factor receptors are known to be
overexpressed on the cell surface of many tumor types. This
394 The Journal of Thoracic and Cardiovascular Surgery ● Auguarticle presents work evaluating which RTKs are present in
MM and their contribution to the constitutive activation of the
PI3K/Akt signaling pathway in this treatment-resistant
neoplasm.
Materials and Methods
Cell Lines
The human mesothelioma cell lines I-45 and REN were main-
tained in RPMI 1640 media supplemented with 10% fetal
bovine serum (FBS), 100 g/mL penicillin, and 100 g/mL
streptomycin and incubated in an atmosphere of 5% carbon
dioxide at 37°C. I-45 is a human sarcomatous-type MM, p53
wild-type (donated generously by Dr Joseph Testa of the Fox
Chase Institute, Philadelphia, Pa). REN is a human epithelial-
type MM and p53 mutant (developed by WRS). The SV40
Tag-transformed human mesothelial cell line Met5a was pur-
chased from American Type Culture Collection (Manassas,
Va). Met5a was maintained in Medium 199 supplemented with
10% FBS, 1 ng/mL epidermal growth factor (EGF), 400 nmol/L
hydrocortisone, 100 g/mL penicillin, and 100 g/mL strepto-
mycin and incubated in an atmosphere of 5% carbon dioxide at
37°C.
Materials
Polyclonal antibodies to phosphorylated Akt (Ser 473), Akt,
insulin-like growth factor (IGF) 1R-, and platelet-derived
growth factor receptor (PDGFR) , as well as anti-rabbit IgG,
were obtained from Cell Signaling (Beverly, Mass). Polyclonal
antibodies to epidermal growth factor receptor (EGFR), HER2/
neu, and actin were obtained from Santa Cruz Biotechnology
(Santa Cruz, Calif). AG 538 (IGF receptor [IGFR] inhibitor) and
AG 1478 (EGFR inhibitor) were obtained from Sigma-Aldrich (St
Louis, Mo). AG 1295 (PDGFR inhibitor) was obtained from
Calbiochem (San Diego, Calif). AG 538, AG 1478, and AG 1295
were reconstituted in dimethyl sulfoxide (DMSO) at concentra-
tions of 82, 16, and 47 mmol/L, respectively, and then further
diluted to desired concentrations in RPMI 1640 media supple-
mented with 10% FBS.
In Vitro Assay of Cellular Viability
The XTT colorimetric assay (Roche Diagnostics, Indianapolis,
Ind) was used to determine cellular viability after treatment
with AG 538, AG 1478, and AG 1295. Cells were plated on
96-well plates at a concentration of 2500 cells per well. After
allowing 24 hours for adherence, cells were treated with serial
dilutions of AG 538 (range, 0-425 mol/L), AG 1478 (range,
0-159 mol/L), AG 1295 (range, 0-215 mol/L), and DMSO
(range, 0%-0.5%) in RPMI plus 10% FBS. Seventy-two hours
after exposure, the XTT assay was performed per protocol
supplied by the manufacturer. In brief, 50 L of XTT reagent
was added to each well, and the plates were incubated at 37°C
for 4 hours. The plates were then analyzed with a colorimetric
microplate reader at a wavelength of 450 nm (Dynatech Labs,
Langley, Va). Analysis of data was performed with Microsoft
Excel (Microsoft Corp, Redmond, Wash). These experiments
were performed in triplicate.
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Western blot analysis was performed with total cell lysates
prepared by lysing plated cell monolayers with sodium dodecylsul-
fate-polyacrylamide gel electrophoresis sample buffer. Samples
were collected when cell monolayers were approximately 70%
confluent to determine the relative expression of EGFR, HER2/
neu, IGFR, and PDGFR in the I-45, REN, and Met5a cell lines.
I-45 and REN cells were plated in RPMI plus 10% FBS and
allowed 24 hours for adherence to determine phosphorylated Akt
and Akt expression after RTK inhibition. Samples were collected
4, 12, and 24 hours after treatment with AG 538 (85 mol/L), AG
1478 (15 mol/L), and AG 1295 (45 mol/L). An untreated
control sample was also collected. The protein content of each cell
lysate was quantified with the BCA protein assay (Pierce, Rock-
ford, Ill). Each lane on a sodium dodecylsulfate polyacrylamide
gel was loaded with 50 g of cell lysate, and the samples were
electrophoresed to separate proteins under reducing conditions.
After electrophoresis, the proteins were transferred to high-bond
nitrocellulose membranes (Amersham, Piscataway, NJ). The mem-
branes were then incubated with primary and secondary antibodies
and developed with the Lumiglo chemiluminescence reagents
(Cell Signaling).
Apoptosis Assay
Apoptotic cell death was evaluated on the basis of changes in
flow cytometric characteristics. Fluorescence-activated cell
sorter (FACS) analysis was performed as follows: after expo-
sure to RTK inhibitors for 96 hours, cells were trypsin digested,
collected by means of centrifugation, resuspended in phos-
phate-buffered saline, and fixed in 70% ethanol at 20°C
overnight. After centrifugation, cells were washed in phos-
phate-buffered saline and resuspended in a propidium iodide
staining solution containing RNase (Roche Diagnostics). Spec-
imens were incubated in the dark for 30 minutes at 37°C and
then analyzed with the use of an EPICS Profile II flow cytom-
eter (Coulter Corp, Hialeah, Fla). An analysis region was set on
the basis of the negative controls, and the percentage of sub-G1
cells was calculated from this region. These experiments were
performed in triplicate. Statistical analysis was performed with
the Student t test.
Results
Mesothelioma Cell Lines Highly Express EGFR,
IGF-1R-, and PDGFR-
Cell lysates from I-45, REN, and Met5a were analyzed by
means of Western blot analysis to determine the relative
expression of EGFR, HER2/neu, IGF-1R-, and PDGFR-
(Figure 1). EGFR is highly expressed in both MM cell lines
in comparison with Met5a, although expression in the epi-
thelial-type line (REN) appears to be greater than in the
sarcomatous-type line (I-45). HER2/neu does not appear to
be highly expressed in either MM cell line. IGF-1R- and
PDGFR- expression appear to be equivalent in I-45 and
REN, with both MM cell lines exhibiting greater expression
than Met5a.
The Journal of ThoraciCellular Viability In Vitro After Receptor Tyrosine
Kinase Inhibition
A colorimetric (XTT) assay was performed to assess the
effects of anti-EGFR (AG 1478), anti-IGFR (AG 538),
and anti-PDGFR (AG 1295) kinase inhibitors on cellular
viability in both MM cell lines. EGFR kinase inhibition
reduced cellular viability in a dose-dependent fashion in
both I-45 and REN cells (Figure 2, A ). Analysis of the
resulting viability curve yielded an inhibitory concentra-
tion of 50% (IC50) dose of 15 mol/L AG 1478 for both
cell lines. IGFR kinase inhibition reduced cellular viability in
a dose-dependent fashion in both MM cell lines, with I-45
displaying increased sensitivity than REN (Figure 2, B). The
IC50 dose of AG 538 was determined to be approximately
85 mol/L for both cell lines. PDGFR kinase inhibition
reduced cellular viability in both I-45 and REN only at
concentrations greater than previously reported.16 The IC50
dose of AG 1295 was determined to be approximately 140
mol/L for both cell lines (Figure 2, C). Tyrosine kinase
inhibitors are known to lose their specificity as their con-
centration increases. Because this concentration is much
higher than the dose previously reported in other tumor
types, we elected to use a more appropriate concentration
for further studies (45 mol/L).
Apoptotic Cell Death After Receptor Tyrosine Kinase
Inhibition
Cellular DNA content was examined with FACS analysis to
determine whether the decrease in cellular viability noted
previously was due to apoptosis. After exposure of mesothe-
lioma cell lines to tyrosine kinase inhibitors for 96 hours,
cell-cycle analysis was performed after propidium iodide
staining to quantify the percentage of cells in the sub-G1
phase (Figure 3). After treatment with AG 1478 (15 mol/
Figure 1. Western blot analysis of receptor tyrosine kinase pro-
tein expression in 2 MM cell lines (I-45 and REN) and a mesothe-
lial cell line (Met5a). EGFR, IGF-1R-, and PDGFR- are highly
expressed in both MM cell lines in comparison with Met5a.
HER2/neu actin is not highly expressed in either MM line. -Actin
expression is shown as a control.L), a significant percentage of cells in both cell lines was
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with a control group treated with DMSO (I-45: 16.6% vs
3.2%, P  .05; REN: 16.9% vs 2.3%, P  .05). AG 538
exposure (85 mol/L) resulted in significant apoptosis in
the sarcomatous line I-45 (24.9% vs 3.2%, P  .05). How-
ever, AG 538 did not result in significant apoptosis in the
epithelial line REN (3.6% vs 2.3%, P  .05). Treatment
with AG 1295 (45 mol/L) did not result in significant
programmed cell death in either cell line (I-45: 3.1% vs
Figure 2. Cell viability assay (XTT) of mesothelioma cel
A, EGFR kinase inhibition (AG 1478) reduced cellular v
(range, 0-159 mol/L). B, IGFR kinase inhibition (AG 53
both MM cell lines, with I-45 displaying greater sen
inhibition (AG 1295) reduced cellular viability in both I
reported in other cell lines (range, 0-215 mol/L). DMSO
0%-0.5%).3.2%, P  .05; REN: 2.4% vs 2.3%, P  .05).
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Cell-surface RTKs are known to activate the PI3K/Akt signal-
ing pathway in a ligand-dependent fashion. Western blot anal-
ysis for phosphorylated Akt was performed on cell lysates after
exposure to tyrosine kinase inhibitors to determine whether
EGFR, IGFR, or PDGFR is responsible for the constitutive
activation of this pathway in mesothelioma (Figure 4). Inhibi-
tion of EGFR tyrosine kinase activity (AG 1478) resulted in
s after exposure to receptor tyrosine kinase inhibitors.
ity in a dose-dependent fashion in both I-45 and REN
uced cellular viability in a dose-dependent fashion in
ty than REN (range, 0-425 mol/L). C, PDGFR kinase
nd REN only at concentrations greater than previously
rier is included as a control for the 3 inhibitors (range,l line
iabil
8) red
sitivi
-45 a
cardecreased signaling through the PI3K pathway in both the I-45
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in phosphorylated Akt on Western blot analysis. Neither IGFR
nor PDGFR inhibition affected the Akt phosphorylation status
in either cell line.
Discussion
Despite advances in modern oncologic care, the prognosis for
patients with MM remains poor. Mesothelioma is typically
resistant to commonly used apoptotic stimuli, such as chemo-
therapy and radiation. Activated PI3K, by way of downstream
effectors, is known to control cellular functions, such as cell-
cycle progression and prevention of apoptosis, in many solid
tumor types. In previous studies our laboratory has demon-
strated that this signaling pathway is constitutively active in
resected mesothelioma specimens and that PI3K inhibition by
means of a small molecular kinase inhibitor (LY294002) or
forced overexpression of a negative regulator (PTEN) engen-
ders apoptotic cell death in mesothelioma cell lines.
Cell-surface receptors for peptide growth factors are known
to activate the PI3K signaling pathway. EGFR is one such
receptor known to be overexpressed at the RNA level, the
protein level, or both by many human malignancies, such as
those of the breast, colon, pancreas, lung, and upper aerodi-
gestive tract.17,18 There are several existing studies that suggest
that EGFR might be important in the pathogenesis of mesothe-
lioma. In 1990, Dazzi and colleagues19 found that 68% of
mesothelioma specimens stained positively for EGFR by
means of immunohistochemistry and that EGFR positivity was
more common in the epithelial subtype. In studying the im-
munohistochemical expression of EGFR and its ligand, trans-
forming growth factor (TGF) , Cai and associates20 found
that 76% of mesotheliomas expressed TGF-, whereas 45%
expressed EGFR, indicating the possibility of an EGFR auto-
crine loop. EGFR expression in mesothelial cells has also been
Figure 3. Sub-G1 fluorescence-activated cell-sorter an
tyrosine kinase inhibitors. The apoptotic percentage o
increased significantly in both I-45 (16.6% vs 3.2%, P<
control. AG 538 (85 mol/L) exposure led to a significan
P < .05) but not REN (3.6% vs 2.3%, P > .05). Treatm
programmed cell death in either I-45 (3.1% vs 3.2%, Plinked to asbestos exposure in tissue culture. Pache and co-
The Journal of Thoraciworkers21 discovered that SV40-transformed human mesothe-
lial cells (Met5a) exposed to asbestos fibers in vitro overex-
pressed EGFR compared with control cells and that EGFR
expression was related to increasing fiber length of crocidolite
asbestos. A similar study confirmed these findings in rat pleu-
ral mesothelial cells.22 Janne and colleagues23 demonstrated
that 4 MM cell lines expressed EGFR and that EGFR inhibi-
Figure 4. Western blot analysis of phosphorylated Akt (P-Akt)
protein expression after exposure of mesothelioma cell lines to
receptor tyrosine kinase inhibitors. A, Inhibition of EGFR tyrosine
kinase activity (AG 1478, 15 mol/L) resulted in decreased sig-
naling through the PI3K pathway in both I-45 and REN, as evi-
denced by a time-dependent decrease in phosphorylated Akt. B
and C, Neither IGFR (AG 538, 85 mol/L) nor PDGFR (AG 1295, 45
mol/L) inhibition affected the phosphorylated Akt status in ei-
ther cell line. Total Akt expression is shown as control and was
after exposure of mesothelioma cell lines to receptor
s 96 hours after exposure to AG 1478 (15 mol/L) was
nd REN (16.9% vs 2.3%, P< .05) compared with DMSO
ease in the apoptotic population in I-45 (24.9% vs 3.2%,
ith AG 1295 (45 mol/L) did not result in significant
5) or REN (2.4% vs 2.3%, P > .05).alysis
f cell
.05) a
t incr
ent w
> .0unaffected by differential treatment.
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cycle arrest. Also, She and associates24 noted that ZD1839
potentiated the radiation response of mesothelioma xenografts
in nude mice, with many animals demonstrating complete
regression with no tumor regrowth.
The IGF-1 receptor is known to mediate PI3K signaling and
is commonly expressed on many tumor types, including breast,
prostate, colon, and lung cancer.25 In 1993, Lee and col-
leagues26 reported that both normal mesothelial and mesothe-
lioma cell lines express IGF-1 and IGF-1R mRNA, indicating
the possibility of an autocrine loop. Also, Pass and associates27
have reported that an IGF-1 receptor antisense expression
vector led to a decrease in proliferation and tumorigenicity in
a hamster mesothelioma cell line.
PDGFR is known to be present on tumor cells, and PDGFR
inhibitors are currently in use in the treatment of chronic
myelogenous leukemia and gastrointestinal stromal tumors.28
Also, activated PDGFR has been shown to induce PI3K sig-
naling.29 In 1991, Versnel and coworkers30 demonstrated that
mesothelioma cell lines express PDGF- receptor mRNA and
protein, whereas normal mesothelial cells express PDGF-
receptors. A similar expression pattern has been demonstrated
in clinical specimens by means of immunohistochemistry.31
Moreover, overexpression of PDGF- through a retroviral
expression vector resulted in tumorigenic conversion of a hu-
man mesothelial cell line.32
In the current study we have demonstrated that the relative
expression of EGFR, IGF-1R, and PDGFR is greater in 2 MM
cell lines in comparison with a transformed mesothelial line.
However, only EGFR appears to be involved in the constitu-
tive activation of the PI3K/Akt pathway noted previously in
mesothelioma. Inhibition of the EGFR tyrosine kinase engen-
ders apoptotic cell death in both mesothelioma cell lines and
leads to downregulation of the PI3K signaling pathway, as
evidenced by Akt hypophosphorylation. Moreover, after stim-
ulation with EGF (10 ng/mL), both I-45 and REN demonstrate
Akt hyperphosphorylation by means of Western blot analysis.
Interestingly, inhibition of IGF-1R resulted in decreased cel-
lular viability and apoptosis in a sarcomatous-type mesotheli-
oma cell line (I-45) but not in an epithelial-type mesothelioma
cell line (REN). IGFR inhibition did not appear to affect PI3K
signaling in either cell line. An inhibitor of PDGFR did not
affect viability, apoptosis, or PI3K signaling in either of the cell
lines. A previous study of signal transduction events after
exposure of rat pleural mesothelial cells to asbestos yielded
similar results. In this study, Zanella and colleagues33 noted
that asbestos fibers induced phosphorylation of mitogen-acti-
vated protein kinase and extracellular signal–regulated kinase
(ERK) 1 and 2. Moreover, they reported that stimulation of
these mesothelial cells with the EGFR ligands EGF and
TGF- similarly induced phosphorylation of ERK 1 and 2,
whereas stimulation with IGF-1 and PDGF isoforms did not
affect ERK phosphorylation status. Our study suggests that
398 The Journal of Thoracic and Cardiovascular Surgery ● Augutherapies targeting EGFR, IGFR, PI3K, and Akt might be
clinically relevant in mesothelioma. Two anti-EGFR therapies
are currently in clinical use: the monoclonal antibody C225
(Erbitux) and the small molecule inhibitor ZD1839 (Iressa).
Targeted therapies for IGFR and Akt are currently in various
stages of development. Certainly further investigation with
such agents in mesothelioma is warranted in an effort to
improve the currently dismal prognosis of this treatment-resis-
tant neoplasm.
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Discussion
Dr Dao M. Nguyen (Bethesda, Md). I just have a few questions for
you regarding the levels of EGFR, PDGFR, or IGFR. You compared
the levels of these receptors on cancer cells with those of transformed
The Journal of Thoracinormal cells. Have you studied the levels of these receptors on
primary normal cells, like skin fibroblasts or keratinocytes, or primary
normal human bronchial epithelial cells?
Dr Rascoe. No, sir, we have not looked at that. As you may
know, mesothelial cells are very difficult to culture in vitro, and
therefore we use a transformed cell line. We have not compared
that with an endothelial cell line or keratinocytes.
Dr Nguyen. Right. I realize that limitation. Any mesenchyma-
derived cells should be a good representation of normal control
cells. The other thing is that you used very high concentrations of
these pharmacologic inhibitors, up to a range of 10 mol/L or
more. How selective are these inhibitors when you use a micro-
molar concentration?
Dr Rascoe. That is a very good point. The IC50 doses for
EGFR and IGFR inhibition that we are reporting are similar to the
doses reported in other tumor types in the literature. However, as
you know, small molecular inhibitors of tyrosine kinases lose
specificity as their concentration is increased. We see EGFR inhi-
bition at approximately 10 mol/L in our cell lines.
Dr Nguyen. That is true and very important because if you try
to translate that to a clinical study, as you know, in the phase
I/phase II Iressa studies, the maximum clinically achievable con-
centration of Iressa is around 2 mol/L.
Dr Rascoe. We are now attempting to confirm these studies
with monoclonal antibodies. As you know, there are anti-EGFR
and IGFR monoclonal antibodies that are commercially available.
These antibodies do not lose specificity with increasing concen-
tration and are therefore a purer inhibitor than the small molecule
inhibitors.
Dr Nguyen. Just a technical point. How good are these PDGFR
antagonists you are using? Have you been able to get the imatinib
mesylate (Gleevec)?
Dr Rascoe. We have not used imatinib mesylate or gefitinib
(Iressa).
Dr W. Roy Smythe (Temple, Tex). I would like to respond to
one of Dao’s questions. I am not sure whether the next presentation
will address this, but we have stained a number of mesothelioma
specimens for EGFR expression, and there is a significant differ-
ence in the tumor and surrounding normal cells in vivo, which I
think is a reasonable way to answer that, although we have not
looked at other normal cell types.
The other thing that Dr Rascoe did not mention about the
selectivity is that if you treat Met5A with the inhibitors that we
have shown here at the same concentrations, there is basically no
effect.
Dr Jack Roth (Houston, Tex). I have just one comment. You
saw a spectrum of sensitivity to these kinase inhibitors, which
is very relevant to the clinical situation, in which many patients
are not very responsive to some of the known kinase inhibitors.
One of the emerging observations here is that there are probably
mutations, for example, in EGFR, and those patients who have
mutations in their tumors in this receptor are the ones who
appear to be responsive. Therefore, I wondered whether you
have had an opportunity to investigate this in some of your
responsive and nonresponsive cell lines. Have you looked at the
status of the receptor? Are there mutations? Are there overex-
pressions? Is there anything that you can think of to explain this
difference in sensitivity?
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TSDr Rascoe. We have not looked specifically at the presence
of mutations. It does appear that in our 2 cell lines, REN and400 The Journal of Thoracic and Cardiovascular Surgery ● Auguanalysis, even in serum-starved cells. Therefore there is a
possibility that the receptor is mutated. However, we have notI-45, EGFR is constitutively phosphorylated on Western blot looked at that yet.st 2005
